After a decade of glooming perspectives, the pharmaceutical
industry is making a strategic shift towards biologics.
Biological drugs are not only a source of targeted and
personalized treatments but also a promising field for
This article will discuss the reappraisal of pharmaceutical R&D and examine the innovative prospects around biological medicines. Moreover, it will present the tax credit opportunities available for companies engaged in eligible biologics R&D activities.
Enacted in 1981, the federal Research
and Development (R&D) Tax Credit allows a credit of up to
13% of eligible spending for new and improved products and
processes. Qualified research must meet the following four
Eligible costs include employee wages, cost of supplies, cost of testing, contract research expenses, and costs associated with developing a patent. On December 19, 2014, President Obama signed the bill extending the R&D Tax Credit for 2014 tax year.
Recent years have brought a wave of optimism over the pharmaceutical industry. Research and development productivity is rising and the perception of long-term trends is increasingly positive. The confident view of pharma stocks, however, hasn't been around for long. The last decade was haunted by the feeling that experimental drugs were not a good investment. As a result, pharmaceutical companies were poorly valued - often at slightly higher than expected sales of existing products.
In a few words, the last decade witnessed a victory of skepticism over innovation. Even though the sales of "blockbuster" drugs enabled companies to invest in new industrialized R&D techniques, which used machines to identify potential new products, efforts proved worthless and returns on investment were disappointing. In a context of "patent cliffs" and consequent competition from generics, one could have believed pharmaceutical companies to be doomed.
Fortunately, the winds have been changing for the
pharmaceutical industry. After a period of pessimism,
investors seem willing to reward commitments to science and
innovation. The proof: since 2012 the price of various
pharmaceutical companies in the equity market has mounted. In
the words of Flemming Ornskov, chief executive at Shire
Pharmaceuticals, "Science is back in the high street. There is
a return to the realization that innovation is the key driver.
(...) it is about creating a differentiated product with
people focused on medical need and comparative data."
Evidence supports this renewed emphasis on R&D. In 2012, the U.S. Food and Drug Administration approved 39 new drugs, an exceptionally high number, since 1996. Figure 1 below, originally published by the Center for Drug Evaluation and Research, presents the number of new medicines approved per year since 2003. Novel medicines are referred to as new molecular entities (NMEs).
The accompanying Figure 1, originally published by the Center for Drug Evaluation and Research, presents the number of new medicines approved per year since 2003. Novel medicines are referred to as new molecular entities (NMEs).
Optimism is not restricted to the U.S. The Deutsche Bank
expects the European-based pharmaceutical companies to
generate around $27billion from new products over the next
three years. The unavoidable question is, what has
A recent shift towards biological drugs can help explain the surge in pharmaceutical R&D productivity. The pursuit of more effective and personalized treatments has lead to a new focus on complex molecules. As a result, pharmaceutical companies are showing unprecedented interest in buying biotechnology companies or licensing their products. Roche and Sanofi, which recently made acquisitions in the biotech field (Genentech and Genzyme, respectively), exemplify this trend.
Also referred to as biologics, proteins, specialty drugs, or "large molecules", biological medicines are medications derived from living material - human, animal, or microorganism. Different from chemically derived drugs, which constitute "small molecules" and present clear-cut chemical structures, biological medicines can be composed of up to 20,000 atoms. With 100 to 1,000 the size of traditional drugs, biologics are much more complex and harder to replicate. Such drugs also interact differently with the body than other medications and are most commonly administered by injection or infusion.
Generally speaking, the benefit/risk comparison for biologics can be significantly better than traditional drugs, often resulting in abbreviated recoveries. This is possible because, unlike chemical-based medicines, biologics are more targeted to diseases. Developed through genetic modification, such drugs present high accuracy as they search for the diseased cells to be treated. Moreover, by accounting for genetic differences, biologics can provide more "personalized" treatments, specially designed for certain subgroups of patients.
Most biologics currently used are monoclonal antibodies
(MABs), including the world's second bestselling drug, Humira.
Different from regular antibodies, which are a part of every
immune system, MABs are modified in order to treat specific
diseases. Thus, they are able to find the diseased area of the
body, including cancer cells. This targeted approach allows
for safer and more effective treatments with fewer side
According to IMS Health, biological drugs already represent about 25% of the $320 billion spent on medications in the U.S. every year. Expectations are that this segment will continue to grow, commanding an even larger share of the prescription drug market in the years to come.
Biological drugs have been largely used to treat a number of
conditions, such as rheumatoid arthritis and psoriasis,
cancer, blood irregularities, and autoimmune and neurological
disorders. The cancer treatments Avastin, Herceptin, and
Rituxan, as well as the drugs for rheumatoid arthritis and
psoriasis, Humira and Enbrel, are good examples of highly
diffused biological medicines.
Currently, half of the world's ten top-selling drugs are biologics.
Figure 2 below, recently
published by professional prognosticator, EvaluatePharma,
presents the complete list of top 10 U.S. drugs:
Biological drugs have emerged as promising alternatives for pharmaceutical companies struggling with patent expirations. The acquisition of Weyth by the giant Pfizer, in 2009, was a clear example of this strategic shift. More recently, Merck announced the construction of a new biologics research facility in Kenilworth, NJ. This was seen as an attempt to overcome the patent loss of the company's successful Singular.
Companies engaged in biologics R&D activities may be
entitled to significant federal tax credits. The following
paragraphs list a few promising domains for innovation
understanding: Understanding the mechanisms involved in
different diseases is key to the development of innovative
biological treatments as well as to the improvement of
existing ones. MedImmune, the global biologics R&D arm of
AstraZeneca, specifies a few indispensable aspects of disease
understanding, notably, therapeutic area-specific biology,
cell biology, pharmacology, pharmacokinetics,
pharmacodynamics, and translational science.
Engineering new therapeutic antibodies: As a result of
R&D efforts, scientists have been able to harness the
innate power of antibodies in order to create medicines,
particularly against cancer. A few molecular engineering
techniques stand out as promising areas for innovation.
Glycoengineered antibodies, for instance, have modified sugar molecules that contribute to enhancing the immune system's ability to attack cancer cells. Similarly, bi-specific antibodies have shown promise as a source of therapy. Designed to recognize two different targets, they may one day constitute powerful tools to fight the multiple mechanisms of cancer.
Some cancer cells, however, do not respond well to typical two armed antibodies. For this reason, R&D efforts have also focused on developing one-armed or monovalent antibodies.
III. Access to
data: Access to larger volumes of information is at the
heart of the emergence of biological drugs. Enhanced capacity
of collecting and processing biomedical data has favored the
development of innovative therapies. The use of systematic
techniques such as electronic medical records and databases
can greatly contribute to further advances in this domain.
Particularly, the conversion to electronic records will help
reduce the gap between Big Data of DNA research and biological
therapies, fostering innovation.
Currently, specific medical software has been developed to assist biologics R&D efforts. Merck & Co., for instance, has worked in partnership with PerkinElmer Informatics to develop a workflow management solution specially tailored for its biologics research. The resulting integrated platform supports structured data, results, and sample tracking in biological drugs R&D. The company expects to benefit from this improved data capturing ability, particularly as a means of assessing productivity and engaging in comparative analyses.
IV. Neurological therapies: With the aging of the baby-boom generation, neurological diseases, such as Alzheimer's, affect a growing number of people. Therefore, biological therapies for brain disorders are an important field for R&D activities.
One major obstacle has hindered the development of such therapies, namely, the blood-brain barrier (BBB). The BBB guarantees the separation of blood and brain extracellular fluid in the central nervous system. It also obstructs the delivery of therapeutic agents to certain regions of the brain.
Recent research in mouse models has shown the potential of
bi-specific antibodies using the transferrin receptor (TfR) to
boost antibody uptake in the brain. However, safety
liabilities need to be addressed before TfR-based therapeutics
are successfully developed.
V. Antibody-Drug Conjugates: According to the American Cancer Society a total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013. Even though important R&D efforts are underway, the challenge of balancing benefits and side effects in cancer treatments is yet to be overcome.
Antibody-drug conjugates (ADCs) are an emerging option for targeted treatment of cancer. ADCs are monoclonal antibodies (mAbs) linked to a biologically active cytoxic (anticancer) payload or drug by chemical linkers with labile bonds. By combining the unique targeting capabilities of mAbs and the cancer-killing properties of cytoxic drugs, ACDs reduce the impact of chemotherapy on healthy cells.
ACDs research and development activities have proved very
promising. This new line of therapy, often referred to as
highly potent biopharmaceutical drugs, is very technically
challenging, as it must combine innovations from biotechnology
and chemistry. Genentech, a leading biotechnology
company headquartered in South San Francisco, CA, currently
has 15 ACDs being studied for 11 types of cancer.
VI. Biosimilars: Biosimilar drugs are copycat "generic" versions of brand-name biologic drugs. As a biological drug, biosimilars are derived from living material - human, animal, or microorganism, which makes them more complex and expensive than traditional drugs. A majority of U.S. states have passed laws favoring biosimilars and the Food and Drug Administration recently approved the first biosimilar drug for distribution in the United States. The widespread introduction of biosimilars could mean lower health care expenses therefore benefiting patients, insurers, and the government.
Many of these biosimilars have been available in Europe for almost a decade, however, the approval of the drugs in the U.S. has been slow coming because until now regulators couldn't figure out how to approve knockoffs that were highly similar but not exact replicas. In Europe, biosimilars typically cost 15% to 30% less than the brands which they replicate. The cost competitiveness of biosimilars could therefore trigger more competition, which would drive down costs in the U.S. which currently spends $376 billion a year on pharmaceuticals . It is estimated that the lower priced biosimilar drugs could save the U.S. $47 billion over the next ten years. Companies investing in biosimilar R&D must focus on safety concerns and on getting the necessary FDA approvals for commercialization.
Biological drugs have restored faith in pharmaceutical
innovation. By combining more effective treatments and reduced
side effects, biologics are conquering an ever-growing share
of the prescription drug market. Investments in R&D
activities have shown great promise, particularly when it
comes to disease understanding, molecular engineering, data
gathering and processing, and the development of biosimilars.
Federal R&D tax credits are available to assist companies
investing in eligible biologics innovation activities.
Charles R Goulding Attorney/CPA, is the President of R&D Tax Savers.
Andressa Bonafé is a Tax Analyst with R&D Tax Savers.
Charles G Goulding is the Manager of R&D Tax Savers.
|The R&D Tax Credit Aspects of Mechatronics|
|The R&D Tax Credit Aspects of Emotion-Recognition Technology|
|The R&D Tax Credit Aspects of Immunology|
|The R&D Tax Credit Aspects of Arthritis|
|The R&D Tax Credit Aspects of Asthma|
|The R&D Tax Credit Aspects of Telemedicine|
|R&D Tax Credits Enhance Life Science Impact Investing|
|The R&D Tax Credit Aspects of Pediatric Hypertension|
|The R&D Tax Credit Aspects of Parkinsons Disease Technology|
|The R&D Tax Credit Aspects of Legal Medical Marijuana|
|Reaching for the Moon: The R&D Tax Credit Aspects of Conquering Cancer|
|The R&D Tax Credit Aspects of Zika|
|The R&D Tax Aspects of CRISPR-CAS9|
|The R&D Tax Credit Aspects of Bioelectronic Medicine|
|The R&D Tax Credit Aspects of Liquid Biopsy Testing|
|The R&D Tax Credit Aspects of Cryogenics|
|The R&D Tax Aspects of Microbiome Research|
|The R&D Tax Aspects of Mouse Models in Clinical Research|
|The R&D Tax Aspects of Precision Medicine|
|The R&D Tax Aspects of Synthetic Biology|
|The R&D Tax Aspects of Pharmaceutical Packaging|
|New Standards and Regulations Create R&D Tax Credit Opportunities for the Pharmaceutical Packaging Industry|
|The R&D Tax Credit Aspects of Orphan Drugs|
|The R&D Tax Credit Aspects of Blood|
|The R&D Tax Aspects of Regenerative Medicine|
|The R&D Tax Credit Aspects of Environmental Remediation|
|The R&D Tax Credit Aspects of Gastro Technology|
|The R&D Tax Credit Aspects of Multiple Sclerosis|
|The R&D Tax Credit Aspects of Concussion Technology|
|The R&D Tax Credit Aspects of Schizophrenia|
|The R&D Tax Aspects of Cancer Treatment|
|The R&D Tax Aspects of the New FDA Mobile Apps Requirements|
|The R&D Tax Credit Aspects of the Medical Software Industry|
|The R&D Tax Aspects of Computer Enabled Human Identification|
|The R&D Tax Credit Aspects of Heart Disease|
|The R&D Tax Credit Aspects of Novel Uses for Genetically Engineered Organisms|
|The R&D Tax Aspects of Respiratory Diseases|
|The R&D Tax Credit Aspects of Cognitive Computing|
|The R&D Tax Credit Aspects of Cosmetics|
|The R&D Tax Credit Aspects of Major Life Science Benefactors|
|The R&D Tax Credit Aspects of the Health Cloud|
|The R&D Tax Credit Aspects of Autism|
|The R&D Tax Credit Aspects of 3D Bioprinting|
|The R&D Credit Aspects of Cell Therapy|
|The R&D Tax Credit Aspects of Sugar Substitution and Reduction in Food Products|
|The R&D Tax Credit Aspects of Gluten-Free Foods|
|R&D Tax Credit Aspects of Sleep Innovation|
|R&D Tax Credit Aspects of Medical Robotics|
|The R&D Tax Aspects of Neuroscience|
|The R&D Tax Credit Aspects of Hearing Technology|
|The R&D Tax Credit Aspects of Eye Disease|
|The R&D Tax Credit Aspects of Dermatology Innovation|
|The R&D Tax Credit Aspects of Bioinformatics|
|The R&D Tax Aspects of Lab Equipment and Instrumentation|
|The R&D Tax Aspects of Salt Reduction|
|The R&D Tax Aspects of Generic Drugs|
|R&D Tax Credit Fundamentals|
|R&D Credits for Companies Combating Superbugs|
|The R&D Tax Credit Aspects of Alzheimers|
|The R&D Tax Aspects of Diabetes|
|The R&D Tax Aspects of Brain Mapping|
|R&D Tax Credit Aspects of Human Body Weight|